PUNCH03: Preliminary results from a phase II study of disitamab vedotin combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

FGFR3-TACC3 represents an oncogenic fusion protein frequently identified in glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell carcinoma, gallbladder cancer, and ...

Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC). New research has identified a ...

The fibroblast growth factor (FGF) family and their four receptors, FGFR1/2/3/4, mediate multiple physiologic processes, including cell migration, proliferation, survival and differentiation. FGFRs ...

The mutational spectrum of fibroblast growth factor receptor 3 (FGFR3) in individuals with achondroplasia. In humans, the mutations associated with achondroplasia patients are mainly located in ...